Advertisement

Applied Health Economics and Health Policy

, Volume 17, Issue 4, pp 513–521 | Cite as

The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration

  • Risha Gidwani-MarszowskiEmail author
  • Douglas K. Owens
  • Jeanie Lo
  • Jeremy D. Goldhaber-Fiebert
  • Steven M. Asch
  • Paul G. Barnett
Original Research Article

Abstract

Background

The release of highly effective but costly medications for the treatment of hepatitis C virus combined with a doubling in the incidence of hepatitis C virus have posed substantial financial challenges for many healthcare systems. We provide estimates of the cost of treating patients with hepatitis C virus that can inform the triage of pharmaceutical care in systems with limited healthcare resources.

Methods

We conducted an observational study using a national US cohort of 206,090 veterans with laboratory-identified hepatitis C virus followed from Fiscal Year 2010 to 2014. We estimated the cost of: non-advanced Fibrosis-4; advanced Fibrosis-4; hepatocellular carcinoma; liver transplant; and post-liver transplant. The former two stages were ascertained using laboratory result data; the latter stages were ascertained using administrative data. Costs were obtained from the Veterans Health Administration’s activity-based cost accounting system and more closely represent the actual costs of providing care, an improvement on the charge data that generally characterizes the hepatitis C virus cost literature. Generalized estimating equations were used to estimate and predict costs per liver disease stage. Missing data were multiply imputed.

Results

Annual costs of care increased as patients progressed from non-advanced Fibrosis-4 to advanced Fibrosis-4, hepatocellular carcinoma, and liver transplant (all p < 0.001). Post-liver transplant, costs decreased significantly (p < 0.001). In simulations, patients were estimated to incur the following annual costs: US $17,556 for non-advanced Fibrosis-4; US $20,791 for advanced Fibrosis-4; US $46,089 for liver cancer; US $261,959 in the year of the liver transplant; and US $18,643 per year after the liver transplant.

Conclusions

Cost differences of treating non-advanced and advanced Fibrosis-4 are relatively small. The greatest cost savings would be realized from avoiding progression to liver cancer and transplant.

Notes

Author Contributions

RGM contributed to the study design, data interpretation, and writing of the manuscript, and is the overall guarantor of this work. PB contributed to the study conceptualization and design, data interpretation, and writing of the manuscript. JL contributed to the data acquisition and analyses, and writing of the manuscript. DO contributed to the funding, study conceptualization, and data interpretation. SA and JGF contributed to the data interpretation.

Compliance with Ethical Standards

Funding

This work was supported by Merit Review Award no. I01 HX000889-1A1 from the US Department of Veterans Affairs Health Services Research and Development Program. Jeremy D. Goldhaber-Fiebert was supported by Grant R01 DA15612-016 from the National Institutes of Health and the National Institute on Aging Career Development Award K01 AG037593-01A1. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US Government.

Ethics Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Conflict of interest

Risha Gidwani-Marszowski, Douglas K. Owens, Jeanie Lo, Jeremy D. Goldhaber-Fiebert, Steven M. Asch, and Paul G. Barnett have no conflicts of interest that are directly relevant to the content of this article.

Data Sharing

The datasets generated during and/or analyzed during the current study are not publicly available because of Veterans Health Administration regulations. Persons who are not approved by the project’s institutional review board are prohibited by the Veterans Health Administration from viewing the underlying data. Additionally, the Veterans Health Administration requires all its data to remain on its own secure servers.

References

  1. 1.
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.CrossRefPubMedGoogle Scholar
  2. 2.
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMedGoogle Scholar
  3. 3.
    Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology. 2013;57(6):2143–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology. 2013;145(4):790–800.e3.CrossRefPubMedGoogle Scholar
  6. 6.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397–406.CrossRefPubMedGoogle Scholar
  8. 8.
    Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407–19.CrossRefPubMedGoogle Scholar
  9. 9.
    Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162(9):619–29.CrossRefPubMedGoogle Scholar
  10. 10.
    Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014;56(1434):5–6.Google Scholar
  12. 12.
    Demko P, Dickson V. Insurers brace for high-cost Sovaldi. Mod Healthc. 2014;44(18):9.Google Scholar
  13. 13.
    Barlas S. States try to control medicaid pharmaceutical costs: numerous, diverse cost pressures force myriad reform efforts. Pharm Ther. 2015;40(4):260–2.Google Scholar
  14. 14.
    Millman J. An $84,000 hepatitis drug is giving states and insurers a major headache. Wonkblog. The Washington Post; Apr 28, 2014.Google Scholar
  15. 15.
    Neuman T, Hoadley J, Cubanski J. The cost of a cure: Medicare’s role in treating hepatitis C. 2014. Health Affairs Blog. Project HOPE: The People-to-People Health Foundation, Inc; Jun 5, 2014.Google Scholar
  16. 16.
    Somashekhar S. Costly hepatitis drug Sovaldi rattles industry. The Washington Post: Health & Science; Mar 1, 2014.Google Scholar
  17. 17.
    Knox R. Medicare struggling with hepatitis-C cure costs. Kaiser Health News; May 12, 2014.Google Scholar
  18. 18.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Etzion O, Ghany MG. A cure for the high cost of hepatitis C virus treatment. Ann Intern Med. 2015;162(9):660–1.CrossRefPubMedGoogle Scholar
  20. 20.
    Senior M. Sovaldi makes blockbuster history, ignites drug pricing unrest. Nat Biotechnol. 2014;32(6):501–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Kuehn BM. Guideline: new HCV drugs should go to sickest patients. JAMA. 2014;312(11):1084–5.CrossRefPubMedGoogle Scholar
  23. 23.
    HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. When and in whom to initiate HCV therapy. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Jul 6, 2016. https://www.hcvguidelines.org/evaluate/when-whom.
  24. 24.
    Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med. 2015;163(3):226–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis. 2015;61(12):1825–30.CrossRefPubMedGoogle Scholar
  27. 27.
    McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011;33(9):1268–80.CrossRefPubMedGoogle Scholar
  28. 28.
    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17(7):531–46.PubMedGoogle Scholar
  29. 29.
    Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56(10):3024–31.CrossRefPubMedGoogle Scholar
  30. 30.
    Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010;13(4):479–86.CrossRefPubMedGoogle Scholar
  31. 31.
    Armstrong EP, Charland SL. Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin. 2004;20(5):671–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. Dis Manag. 2002;5(2):95–107.CrossRefGoogle Scholar
  33. 33.
    Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002;40(8):675–85.CrossRefPubMedGoogle Scholar
  34. 34.
    O’Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40(5 Pt 2):1620–39.CrossRefPubMedGoogle Scholar
  35. 35.
    Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol. 1999;52(2):137–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Gologorsky Y, Knightly JJ, Lu Y, Chi JH, Groff MW. Improving discharge data fidelity for use in large administrative databases. Neurosurg Focus. 2014;36(6):E2.CrossRefPubMedGoogle Scholar
  37. 37.
    Iezzoni LI. Assessing quality using administrative data. Ann Intern Med. 1997;127(8 Pt 2):666–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Geraci JM, Ashton CM, Kuykendall DH, Johnson ML, Wu L. International Classification of Diseases, 9th Revision, Clinical Modification codes in discharge abstracts are poor measures of complication occurrence in medical inpatients. Med Care. 1997;35(6):589–602.CrossRefPubMedGoogle Scholar
  39. 39.
    Fonarow GC, Saver JL, Smith EE, Broderick JP, Kleindorfer DO, Sacco RL, et al. Relationship of national institutes of health stroke scale to 30-day mortality in medicare beneficiaries with acute ischemic stroke. J Am Heart Assoc. 2012;1(1):42–50.CrossRefPubMedGoogle Scholar
  40. 40.
    Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.CrossRefPubMedGoogle Scholar
  41. 41.
    Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20(1):40–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, et al. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. J Viral Hepat. 2015;22(5):489–95.CrossRefPubMedGoogle Scholar
  44. 44.
    Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, et al. Effect of interferon-free regimens on disparities in hepatitis C treatment of US veterans. Value Health. 2018;21(8):921–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Graham J. Medicaid, private insurers begin to lift curbs on pricey hepatitis C drugs. Kaiser Family Foundation. Kaiser Health News; Jul 5, 2016.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.VA Health Economics Resource Center, VA Palo Alto Health Care SystemMenlo ParkUSA
  2. 2.VA Center for Innovation to Implementation, VA Palo Alto Health Care SystemMenlo ParkUSA
  3. 3.Division of Primary Care and Population Health, Department of MedicineStanford University School of MedicineStanfordUSA
  4. 4.Center for Primary Care and Outcomes Research/Center for Health Policy, Department of MedicineStanford UniversityStanfordUSA

Personalised recommendations